¹û¶³ÊÓƵ

¹û¶³ÊÓƵ to present at H.C. Wainwright 2nd Annual Psychedelics Conference and Stifel 2nd Annual Conference “The Future of Healthcareâ€

July 11, 2022
December 2, 2021

H.C. Wainwright 2nd Annual Psychedelics Conference Presentation:

  • The presentation will be available on-demand on the conference platform from Monday, December 6th, 2021, 7:00 am ET / 12:00 pm GMT
  • To register for the conference, please click

Stifel 2nd annual conference The Future of Healthcare:

  • Date: Wednesday, December 8th, 2021, 1:30 pm ET / 6:30 pm GMT
  • To register for the webcast, click
  • The presentation and a replay of the webcast will be available on ¹û¶³ÊÓƵ’s website shortly after the event

To request a one-on-one meeting with the ¹û¶³ÊÓƵ management team, please email: gvanrenterghem@lifesciadvisors.com.

-Ends-

¹û¶³ÊÓƵ - www.beckleypsytech.com

¹û¶³ÊÓƵ is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. ¹û¶³ÊÓƵ was founded in 2019 leveraging some of the expertise developed over more than 20 years by the ¹û¶³ÊÓƵ Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

Contacts

¹û¶³ÊÓƵ
Cosmo Feilding Mellen
Chief Executive Officer
info@beckleypsytech.com

Communications
FTI Consulting
Ben Atwell / Mike Trace
+44 (0)20 3727 1000
beckleypsytech@fticonsulting.com

Investor Relations
LifeSci Advisors
Guillaume van Renterghem
+41 76 735 01 31
gvanrenterghem@lifesciadvisors.com

â€

Read on

Related posts